Levofolinic acid - Acrotech Biopharma
Alternative Names: Calcium levofolinate; Calcium levoleucovorin; FUSILEV; Isovorin; KHAPZORY; Levofolinate; Levofolinate calcium; Levoleucovorin; Levoleucovorin calcium pentahydrateLatest Information Update: 05 Nov 2023
At a glance
- Originator Wyeth
- Developer Acrotech Biopharma
- Class Antidotes; Antineoplastics; Formyltetrahydrofolates; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anaemia; Colorectal cancer; Osteosarcoma
Most Recent Events
- 06 Mar 2019 Spectrum Pharmaceuticals completes sale of levofolinic acid to Acrotech Biopharma
- 17 Jan 2019 Spectrum Pharmaceuticals and Acrotech Biopharma enters into a definitive agreement to sell Levofolinic acid
- 08 Nov 2018 Spectrum Pharmaceuticals plans to launch levofolinic acid in first quarter of 2019